Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- 5‐FU/cisplatin/anthracycline combinations vs 5‐FU/cisplatin combinations (without anthracyclines) · Overall survival
  Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
  HR 0.74 [0.61, 0.89]
  4 studies · 579 participants
  Moderate
Direct match · question page
- 5‐FU/cisplatin/anthracycline combinations vs 5‐FU/anthracycline combinations (without cisplatin) · Overall survival
  Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
  HR 0.82 [0.73, 0.92]
  7 studies · 1147 participants
  Low

5‐FU/cisplatin/anthracycline combinations vs 5‐FU/anthracycline combinations (without cisplatin)

Overall survival · people with advanced gastric cancer

5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.82 [0.73, 0.92]
7 studies · 1147 participants
Low

5‐FU/cisplatin/anthracycline combinations vs 5‐FU/cisplatin combinations (without anthracyclines)

Overall survival · people with advanced gastric cancer

5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.74 [0.61, 0.89]
4 studies · 579 participants
Moderate